BioLineRx to Report Second Quarter 2015 Results on August 20, 2015
Management to hold a conference call at
The Company will host a conference call on
A replay of the conference call will be available approximately two
hours after completion of the live conference call at www.biolinerx.com.
A dial-in replay of the call will be available until
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
BioLineRx’s current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for acute myeloid leukemia (AML), and has successfully completed a Phase 1 study in stem cell mobilization; BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study; and BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria).
In
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s
View source version on businesswire.com: http://www.businesswire.com/news/home/20150813005403/en/
Source:
Tiberend
Strategic Advisors, Inc.
Joshua Drumm, Ph.D., +1-212-375-2664
jdrumm@tiberend.com
or
Andrew
Mielach, +1-212-375-2694
amielach@tiberend.com
or
BioLineRx
Ltd.
Tsipi Haitovsky, +972-3-6240871
Public Relations
tsipihai5@gmail.com